Abiraterone vs Enzalutamide Among US Veterans With Metastatic Hormone-Sensitive Prostate Cancer
This cohort study found that abiraterone and enzalutamide had comparable outcomes in a first-line mHSPC setting, with similar g-rates and OS in both White and African American patients. There were no differences in survival or g-rate between treatment based on race, comorbidities, and prostate cancer features, including Gleason score, PSA, and volume of disease.
Authors
- Mengxi Zhou (ORCID: https://orcid.org/0000-0003-3901-5149)
- Tito Fojo (ORCID: https://orcid.org/0000-0002-8083-2688)
- Susan E. Bates (ORCID: https://orcid.org/0000-0001-6708-0330)
- Harshraj Leuva (ORCID: https://orcid.org/0000-0002-8860-1382)
- Izak Faiena (ORCID: https://orcid.org/0000-0001-6095-2757)
- Prabhjot Singh Mundi (ORCID: https://orcid.org/0000-0001-9871-4463)
- Martin William Schoen (ORCID: https://orcid.org/0000-0001-6388-5553)
- Yeun‐Hee Anna Park (ORCID: https://orcid.org/0000-0001-9343-231X)
- Benjamin A. Teply (ORCID: https://orcid.org/0000-0002-7366-6212)
- Carol Luhrs
Institutions
- SUNY Downstate Health Sciences University (US)
- Columbia University Irving Medical Center (US)
- VA NY Harbor Healthcare System (US)
- St. Louis VA Medical Center (US)
- James J. Peters VA Medical Center (US)
- Herbert Irving Comprehensive Cancer Center
- Saint Louis University (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.40730
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- U.S. Department of Defense
- U.S. Department of Veterans Affairs
- Prostate Cancer Foundation
- Conquer Cancer Foundation
- Eli Lilly and Company
- Pfizer
- Sanofi
- American Society of Clinical Oncology
- Exelixis
- Seagen
- Astellas Pharma